10.1038/s41586-020-2569-1
10.1038/s41586-020-2569-1 · doi-reference
10.1002/hep.24537
10.1002/hep.24537 · doi-reference
10.1073/pnas.0710981105
10.1073/pnas.0710981105 · doi-reference
10.1021/jm7015864
10.1021/jm7015864 · doi-reference
10.1007/s10620-016-4143-0
10.1007/s10620-016-4143-0 · doi-reference
10.1002/hep.29569
10.1002/hep.29569 · doi-reference
10.1053/j.gastro.2014.12.005
10.1053/j.gastro.2014.12.005 · doi-reference
10.1021/np100489u
10.1021/np100489u · doi-reference
Andrographolide: chemical modification and its effect on biological activities
10.1016/j.bioorg.2019.103511 · doi-reference
10.1021/acsmedchemlett.0c00640
10.1021/acsmedchemlett.0c00640 · doi-reference
10.1074/jbc.m209323200
10.1074/jbc.m209323200 · doi-reference
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
10.1038/ncomms10166 · doi-reference
10.1111/joim.12140
10.1111/joim.12140 · doi-reference
10.1021/acsmedchemlett.8b00534
10.1021/acsmedchemlett.8b00534 · doi-reference
10.1016/j.bmc.2014.04.014
10.1016/j.bmc.2014.04.014 · doi-reference
10.1016/j.bmc.2018.07.017
10.1016/j.bmc.2018.07.017 · doi-reference
Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates
10.1016/j.ejphar.2013.10.048 · doi-reference
10.1126/science.1072891
10.1126/science.1072891 · doi-reference
10.1021/acs.jmedchem.5b00342
10.1021/acs.jmedchem.5b00342 · doi-reference
HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter
10.1016/j.metabol.2018.03.016 · doi-reference
10.1371/journal.pone.0030443
10.1371/journal.pone.0030443 · doi-reference
10.1177/0960327118817862
10.1177/0960327118817862 · doi-reference
Protein expression profiling identifies key proteins and pathways involved in growth inhibitory effects exerted by guggulsterone in human colorectal cancer cells
10.3390/cancers11101478 · doi-reference
Farnesoid X receptor agonists as therapeutic target for cardiometabolic diseases
10.3389/fphar.2020.01247 · doi-reference
10.1080/07391102.2018.1462735
10.1080/07391102.2018.1462735 · doi-reference
10.1021/jm501273r
10.1021/jm501273r · doi-reference
Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling
10.1371/journal.pone.0129866 · doi-reference
10.3390/nu11051132
10.3390/nu11051132 · doi-reference
10.1124/mol.110.064501
10.1124/mol.110.064501 · doi-reference
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
10.1038/srep42801 · doi-reference
10.1681/asn.2017020222
10.1681/asn.2017020222 · doi-reference
Structural investigation for optimization of anthranilic acid derivatives as partial FXR agonists by in silico approaches
10.3390/ijms17040536 · doi-reference
Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists
10.2174/1568026614666141112103516 · doi-reference
Target profile prediction: cross-activation of peroxisome proliferator-activated receptor (PPAR) and farnesoid X receptor (FXR)
10.1002/minf.200900009 · doi-reference
A new FXR ligand chemotype with agonist/antagonist switch
10.1021/acsmedchemlett.0c00647 · doi-reference
10.1002/cpdd.762
10.1002/cpdd.762 · doi-reference
10.1002/hep.30509
10.1002/hep.30509 · doi-reference
Nonsteroidal FXR ligands: current status and clinical applications
10.1007/164_2019_232 · doi-reference
10.1021/ci300459k
10.1021/ci300459k · doi-reference
10.1016/s0092-8674(00)00062-3
10.1016/s0092-8674(00)00062-3 · doi-reference
